Cereno Scientific obtains first patent for drug candidate HDAC inhibitor CS014 in development for thrombosis prevention treatment
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that drug candidate CS014, a novel HDAC inhibitor, has obtained an issued patent in the UK. This is the drug candidate’s first patent that strengthens the positioning of CS014, which is currently in the preparatory stages of a Phase I study and being developed to effectively prevent thrombosis without increasing the risk of bleeding.“This is a significant milestone for our CS014 project. We have with this started to build strong intellectual